The company discontinues one of its two KRAS G12D degraders. 

But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.

So who else could be interested in the oestrogen degrader?

If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.

Weeks after criticising the group’s big pharma partner, John Houston is on his way out.

Any hopes of differentiation could come down to side effects.

Conference activity picks up, with the big one – ASCO – at the end of the month.

Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.

The company is stepping back in second-line breast cancer.